LifeVantage Corporation (FRA:L2T1)

Germany flag Germany · Delayed Price · Currency is EUR
5.70
+0.35 (6.54%)
At close: Dec 4, 2025
-62.25%
Market Cap 75.91M
Revenue (ttm) 195.07M
Net Income (ttm) 8.64M
Shares Out n/a
EPS (ttm) 0.66
PE Ratio 8.79
Forward PE 6.18
Dividend 0.16 (2.90%)
Ex-Dividend Date Dec 1, 2025
Volume n/a
Average Volume 213
Open 5.70
Previous Close 5.35
Day's Range 5.70 - 5.70
52-Week Range 5.25 - 25.00
Beta n/a
RSI 44.29
Earnings Date Feb 3, 2026

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre- and pro-biotics and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fati... [Read more]

Industry Pharmaceutical Preparations
CEO Steven Fife
Employees 238
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol L2T1
Full Company Profile

Financial Performance

In 2025, LifeVantage's revenue was $228.53 million, an increase of 14.17% compared to the previous year's $200.16 million. Earnings were $9.81 million, an increase of 233.84%.

Financial numbers in USD Financial Statements

News

There is no news available yet.